Menu

Layoffs, Restructuring at GSK

GlaxoSmithKline is eliminating 900 US jobs—most in R&D.

Dec 4, 2014
Tracy Vence

WIKIMEDIA, BRADLEY JDrug giant GlaxoSmithKline (GSK) said it will be eliminating 900 US employees in restructuring its research and development (R&D) efforts, among other things, FierceBiotech reported. But not all 900 will be laid off, GSK said, noting some employees may be relocated to other facilities. The firm’s Research Triangle Park, North Carolina, facility will be hit hardest by the changes.

“The details are still unfolding, but we expect as part of this restructure existing roles will be lost in our US R&D and commercial organizations by the end of 2015,” a GSK spokesperson told The Wall Street Journal’s Pharmalot.

“Some R&D roles will be relocated to the Philadelphia area, and some staff will be offered relocation,” GSK told Fierce. “Cuts are not being made across the board but are strategic, focused changes to allow GSK to operate more efficiently. . . . This is a rescaling of work to reflect market forces that were anticipated but that have accelerated and are affecting the entire industry.”

Hints at changes to come at the pharmaceutical firm came earlier this year. In April, GSK and Novartis agreed to swap assets totaling more than $20 billion. Novartis said it would buy GSK’s oncology business, while GSK agreed to purchase Novartis’s vaccines division.

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.